Dr. Daria Fedyukina joined ARPA-H in September 2023 from Case Western Reserve University, where she served as a translational officer in the School of Medicine. Prior to that, she worked in the commercial and portfolio planning division of REGENXBIO, where she was responsible for portfolio expansion and for assessing the technical and commercial potential of gene therapies. Before REGENXBIO, she was a management consultant at global consulting firm L.E.K. Consulting. Fedyukina is also the founder of BioHeights, a consulting company that provides portfolio, R&D, and commercial strategy services to biopharmaceutical companies as well as licensing partner scouting and technology commercialization services to academic institutions. Fedyukina specializes in translational science and commercialization strategies involving cell and gene therapies. She earned a doctorate in chemistry from the University of Wisconsin-, Madison, where her research spanned organic synthesis, protein folding, and nuclear magnetic resonance imaging of proteins. She was a research scientist at LG Chemical Ltd. and ChemBridge Corporation. Fedyukina has helped bring a variety of innovative therapies to market over her career and is committed to making better health care more accessible for all.